Skip to content
DataLookout
Menu

NCT07687667

Effects of GLP-1RAs on Fertility Outcomes in Obese Women With PCOS

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Eligibility criteria expanded, about 5 words
    • Trial sites expanded: 1 → 5 locations
    • Start date changed from estimate of Jul 2026 to Jul 7, 2026
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Ongoing Pregnancy Rate
Timeframe: First cycle of IVF/ICSI-ET (the first frozen-thawed embryo transfer cycle if all embryos are cryopreserved after oocyte retrieval)

Arms and interventions

Experimental: GLP-1 RAs combined with healthy lifestyle educationExperimental

Benaglutide injection (Fisuomei®, National Medicine Standard No. S20230042, Shanghai Renhui Biopharmaceutical Co., Ltd.) was administered at an initial dose of 0.06 mg per injection, three times daily, via subcutaneous injection 5 minutes before meals. After establishing tolerance, the dose was increased weekly by 0.04 mg per injection, reaching 0.2 mg per injection after four weeks, administered three times daily for a total of 12 weeks.Assisted reproductive treatment was initiated upon completion of the 12-week intervention.

metformin and healthy lifestyle educationActive comparator

Metformin hydrochloride (Glucophage®, National Medicine Standard No. H20023370, Shanghai Bristol-Myers Squibb Pharmaceuticals Co., Ltd.) was administered at a dose of 0.5 g twice daily for 12 weeks, taken with meals. Assisted reproductive treatment was initiated upon completion of the 12-week intervention.

Drugs: GLP-1 receptor agonist, Metformin

Sites

5 sites in 1 country